Deepcell and InGel Therapeutics partner to advance ocular cell therapies

Deepcell, a company specialising in AI-powered, label-free single cell morphology profiling and sorting, will provide its REM-I platform to integrate into InGel Therapeutics’ therapeutic development pipeline. The companies said the REM-I platform enables high-dimensional morphological insights that accelerate discovery and optimisation of cell therapy candidates. InGel Therapeutics focuses on engineered, intravitreally delivered cell therapies for […] The post Deepcell and InGel Therapeutics partner to advance ocular cell therapies appeared first on Longevity.Technology.